These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparative bioavailability of furosemide from solution and 40 mg tablets with different dissolution characteristics following oral administration in normal men. Waller ES; Crismon ML; Smith RV; Bauza MT; Doluisio JT Biopharm Drug Dispos; 1988; 9(2):211-8. PubMed ID: 3370308 [TBL] [Abstract][Full Text] [Related]
3. Assessment of pharmaceutical quality of furosemide tablets from multinational markets. Qureshi SA; McGilveray IJ Drug Dev Ind Pharm; 1998 Nov; 24(11):995-1005. PubMed ID: 9876554 [TBL] [Abstract][Full Text] [Related]
4. Bioavailability of seven furosemide tablets in man. Straughn AB; Wood GC; Raghow G; Meyer MC Biopharm Drug Dispos; 1986; 7(2):113-20. PubMed ID: 3708119 [TBL] [Abstract][Full Text] [Related]
5. Impact of chitosan as a disintegrant on the bioavailability of furosemide tablets: in vitro evaluation and in vivo simulation of novel formulations. Rasool BK; Fahmy SA; Galeel OW Pak J Pharm Sci; 2012 Oct; 25(4):815-22. PubMed ID: 23009999 [TBL] [Abstract][Full Text] [Related]
6. In vivo/in vitro correlations for four differently dissolving ketorolac tablets. Gordon MS; Chowhan Z Biopharm Drug Dispos; 1996 Aug; 17(6):481-92. PubMed ID: 8866039 [TBL] [Abstract][Full Text] [Related]
7. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine. Jantratid E; Prakongpan S; Amidon GL; Dressman JB Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285 [TBL] [Abstract][Full Text] [Related]
8. Bioequivalence evaluation of two brands of furosemide 40 mg tablets (Salurin and Lasix) in healthy human volunteers. Najib N; Idkaidek N; Beshtawi M; Bader M; Admour I; Alam SM; Zaman Q; Dham R Biopharm Drug Dispos; 2003 Sep; 24(6):245-9. PubMed ID: 12973821 [TBL] [Abstract][Full Text] [Related]
9. Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide. Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V Int J Clin Pharmacol Ther; 1998 Apr; 36(4):231-8. PubMed ID: 9587051 [TBL] [Abstract][Full Text] [Related]
10. Prolonged-release hydroxypropyl methylcellulose matrix tablets of furosemide for administration to dogs. Smal J; Marvola M; Liljequist C; Happonen I J Vet Pharmacol Ther; 1996 Dec; 19(6):482-7. PubMed ID: 8971678 [TBL] [Abstract][Full Text] [Related]
11. In vivo pharmacokinetic-pharmacodynamic relationship and in vitro equivalence of two oral furosemide tablet formulations. Cuadrado A; Rodríguez Gascón A; Hernández RM; Castilla AM; de la Maza A; Yánez C; López de Ocáriz A; Solinís MA; Pedraz JL Arzneimittelforschung; 2003; 53(5):321-9. PubMed ID: 12854359 [TBL] [Abstract][Full Text] [Related]
12. A bioequivalence study of two products of furosemide tablets. Awad R; Arafat T; Saket M; Saleh M; Gharaibeh M; Zmeili S; Sallam E; Shubair M; Qobrosi S Int J Clin Pharmacol Ther Toxicol; 1992 Jan; 30(1):18-23. PubMed ID: 1551740 [TBL] [Abstract][Full Text] [Related]
13. Bioavailability and pharmacokinetics of furosemide marketed in Thailand. Kaojarern S; Poobrasert O; Utiswannakul A; Kositchaiwat U J Med Assoc Thai; 1990 Apr; 73(4):191-7. PubMed ID: 2394955 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic properties and bioequivalence of 2 formulations of valsartan 160-mg tablets: A randomized, single-dose, 2-period crossover study in healthy Korean male volunteers. Kim JE; Ki MH; Yoon IS; Cho HJ; Kim RS; Tae Kim G; Kim DD Clin Ther; 2014 Feb; 36(2):273-9. PubMed ID: 24529292 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of an oral frusemide/amiloride combination tablet. Brooks SG; Christie RB; Roche J; Fairhead AP; Muirhead D; Townsend HA; Shaw HL Curr Med Res Opin; 1984; 9(2):141-6. PubMed ID: 6399890 [TBL] [Abstract][Full Text] [Related]
16. Bioavailability and diuretic effect of furosemide following administration of tablets and retarded capsules to human subjects. Yagi N; Kiuchi T; Satoh H; Terashima Y; Kenmotsu H; Sekikawa H; Takada M Biol Pharm Bull; 1996 Apr; 19(4):616-22. PubMed ID: 8860970 [TBL] [Abstract][Full Text] [Related]
17. The pharmaceutical and biological availability of commercial preparations of furosemide. Stüber W; Mutschler E; Steinbach D Arzneimittelforschung; 1982; 32(6):693-7. PubMed ID: 6889429 [TBL] [Abstract][Full Text] [Related]
18. Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach. Otsuka K; Wagner C; Selen A; Dressman J J Pharm Pharmacol; 2015 May; 67(5):651-65. PubMed ID: 25644429 [TBL] [Abstract][Full Text] [Related]
19. Dosage variability of veterinary drug products, containing furosemide, linked to tablet splitting. Maggi L; Friuli V; Perugini P; Musitelli G; Venco L Open Vet J; 2021; 11(3):471-482. PubMed ID: 34722213 [TBL] [Abstract][Full Text] [Related]
20. Determination of bioequivalence of two furosemide preparations; the effect of high doses of furosemide on some pharmacokinetic parameters. Wolf-Coporda A; Lovrić Z; Huić M; Francetić I; Vrhovac B; Plavsić F; Skreblin M Int J Clin Pharmacol Res; 1996; 16(4-5):83-8. PubMed ID: 9172005 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]